Regulatory Ahead of ASCO data drop, AZ gets key Imfinzi approval PharmaphorumAstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Medicare Advantage Out-of-Pocket Limits: Variation and TrendsNext: GSK’s Nucala secures NICE COPD endorsement Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
